Thus, in conclusion, the PI3K/Akt signaling pathway should be considered as a target in the treatment of breast cancer, although additional studies are first required to determine the mechanism via which FOXP1 is regulated by the PI3K/Akt/p70S6K signaling pathway. This evidence concerns the gene FOXP1 and breast carcinoma.